Chinese pharma firm 3SBio at 4-week high ahead of product launch
26/06/2019 04:42
** Shares of biopharmaceutical firm 3SBio Inc 1530.HK rise
as much as 4.9% to HK$13.78, their highest since May 28
** The Liaoning-based company says the National Medical
Products Administration has issued the Certificate of Good
Manufacturing Practices for Pharmaceutical Products in China for
the firm's Xenopax, which is used for prevention of acute
rejection of kidney transplantation https://bit.ly/2ZQbIki
** Co says it is actively preparing for the product launch
and sales
** As of Tuesday's close, stock up 30.9% so far this year
** 3SBio has underperformed the Hang Seng Commerce &
Industry Index sector .HSNC by 3.6 percentage points in the
past one month
** The Hong Kong Hang Seng Commerce & Industry Index .HSNC
gains 0.4%, and the benchmark index .HSI edges up 0.1%
(Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)